PubRank

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Clinical Trial ID NCT02048709

PubWeight™ 12.95‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02048709

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 2015 1.22
2 Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res 2015 1.09
3 Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014 1.01
4 Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol 2015 0.91
5 From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016 0.90
6 Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015 0.88
7 Small molecule drugs with immunomodulatory effects in cancer. Hum Vaccin Immunother 2015 0.86
8 O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur J Med Chem 2015 0.84
9 Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 2016 0.84
10 Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015 0.84
11 Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology 2015 0.81
12 Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. Front Immunol 2014 0.80
13 Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol 2016 0.79
14 Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery. Int J Neuropsychopharmacol 2016 0.78
15 Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol 2016 0.75
Next 100